Stephen Frasier Kry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephen Frasier Kry has a total of 484 co-authors. Here are the top co-authors by number of shared publications:
David S. Followill
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center
32 shared publicationsRebecca M. Howell
Department of Radiation Physics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 USA
25 shared publicationsMohammad Salehpour
Department of Radiation Physics; The University of Texas M.D. Anderson Cancer Center; Houston TX USA
17 shared publicationsDavid Followill
Imaging and Radiation Oncology Core, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
16 shared publicationsAndrea Molineu
Department of Radiation Physics. The University of Texas MD Anderson Cancer Center, Houston, USA
13 shared publications- Oleg N. Vassiliev
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
13 shared publications
Latest Publications
- 19 June 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 223, 111649
Dose delivery accuracy of advanced radiotherapy: 30 years of end-to-end dosimetry audits
- 19 June 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 223, 111649
Dose delivery accuracy of advanced radiotherapy: 30 years of end-to-end dosimetry audits
- 17 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104215
Current Practice for Electronic Medical Device Management in Radiation Therapy
- 17 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104215
Current Practice for Electronic Medical Device Management in Radiation Therapy
- 10 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (14) , 1376-1378
Reply to: Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer
- 10 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (14) , 1376-1378
Reply to: Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer
- 2 February 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 218, 111407
A comparison of sensitivity and specificity of dosimetry audits for intensity modulated radiation therapy used internationally for clinical trial credentialing
- 2 February 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 218, 111407
A comparison of sensitivity and specificity of dosimetry audits for intensity modulated radiation therapy used internationally for clinical trial credentialing
- Open Access
- 2 January 2026
- Published by Elsevier in International Journal of Particle Therapy
- Vol. 19, 101297
Trends and Challenges: A 15-Year Review of Imaging and Radiation Oncology Core Anthropomorphic Phantom Audits for Proton Therapy
- 2 January 2026
- Published by Elsevier in International Journal of Particle Therapy
- Vol. 19, 101297
Open AccessTrends and Challenges: A 15-Year Review of Imaging and Radiation Oncology Core Anthropomorphic Phantom Audits for Proton Therapy
- Open Access
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (31) , 3403-3421
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report
PURPOSE: Among childhood cancer survivors, we evaluated not previously explored relationships between colorectal subsequent malignant neoplasm (SMN) incidence and colorectum-specific radiation dose metrics currently used in radiation therapy (RT) planning and expanded upon previously reported chemotherapy associations. METHODS: The Childhood Cancer Survivor Study (CCSS) includes 5-year survivors of childhood cancer diagnosed between 1970 and 1999. RT was assessed as mean colorectal dose (MCD) and the percent volume (V X Gy ) receiving ≥5, 10, 20, 30, and 40 Gy. Chemotherapy was assessed as cumulative doses for procarbazine and platinum agents, cyclophosphamide-equivalent doses for alkylating agents, and doxorubicin-equivalent doses for anthracyclines. Piecewise-exponential models and excess rate ratio (ERR) models evaluated dose-response relationships for the incidence of colorectal SMNs. Reference groups were those not receiving the assessed treatment(s). RESULTS: Among 25,723 survivors (median follow-up = 28.5 years; range = 5.0-48.9), 104 colorectal SMNs were identified. A dose-response relationship was observed between MCD and colorectal SMN rates; incidence rate ratios (IRRs) for 10 to 20 Gy IRRs were 3.8 (95% CI, 1.9 to 7.6), 4.9 (95% CI, 2.0 to 12.0), and 8.7 (95% CI, 3.5 to 21.6) for irradiated volumes of 20% to 2 , 3.7 (95% CI, 2.2 to 6.4) for cyclophosphamide-equivalent dose ≥6,000 mg/m 2 , and 4.5 (95% CI, 2.0 to 10.1) for platinum dose ≥450 mg/m 2 . For procarbazine dose, the IRR was 6.3 (95% CI, 3.0 to 13.2) for 4,200 to 2 and 9.0 (95% CI, 4.3 to 18.9) for ≥7,036 mg/m 2 . In the absence of RT, colorectal SMN rates increased with exposure to any platinum-based agent (IRR, 3.8 [95% CI, 1.1 to 12.7]), alkylator (IRR, 4.8 [95% CI, 1.6 to 14.4]), or procarbazine (IRR, 16.9 [95% CI, 5.9 to 48.8]). Colorectal SMN rates increased linearly with procarbazine dose (ERR per 1,000 mg/m 2 = 73.0 [95% CI, 26.4% to 119.6%]) and MCD (ERR per 1 Gy = 20.8 [95% CI, 9.0% to 32.5%]). Quadratic ERR models did not improve data fit compared with linear ERR models. CONCLUSION: These RT and chemotherapy dose-response relationships can better inform contemporary RT planning for pediatric patients and surveillance guidelines for high-risk survivors.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (31) , 3403-3421
Open AccessColorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report
PURPOSE: Among childhood cancer survivors, we evaluated not previously explored relationships between colorectal subsequent malignant neoplasm (SMN) incidence and colorectum-specific radiation dose metrics currently used in radiation therapy (RT) planning and expanded upon previously reported chemotherapy associations. METHODS: The Childhood Cancer Survivor Study (CCSS) includes 5-year survivors of childhood cancer diagnosed between 1970 and 1999. RT was assessed as mean colorectal dose (MCD) and the percent volume (V X Gy ) receiving ≥5, 10, 20, 30, and 40 Gy. Chemotherapy was assessed as cumulative doses for procarbazine and platinum agents, cyclophosphamide-equivalent doses for alkylating agents, and doxorubicin-equivalent doses for anthracyclines. Piecewise-exponential models and excess rate ratio (ERR) models evaluated dose-response relationships for the incidence of colorectal SMNs. Reference groups were those not receiving the assessed treatment(s). RESULTS: Among 25,723 survivors (median follow-up = 28.5 years; range = 5.0-48.9), 104 colorectal SMNs were identified. A dose-response relationship was observed between MCD and colorectal SMN rates; incidence rate ratios (IRRs) for 10 to 20 Gy IRRs were 3.8 (95% CI, 1.9 to 7.6), 4.9 (95% CI, 2.0 to 12.0), and 8.7 (95% CI, 3.5 to 21.6) for irradiated volumes of 20% to 2 , 3.7 (95% CI, 2.2 to 6.4) for cyclophosphamide-equivalent dose ≥6,000 mg/m 2 , and 4.5 (95% CI, 2.0 to 10.1) for platinum dose ≥450 mg/m 2 . For procarbazine dose, the IRR was 6.3 (95% CI, 3.0 to 13.2) for 4,200 to 2 and 9.0 (95% CI, 4.3 to 18.9) for ≥7,036 mg/m 2 . In the absence of RT, colorectal SMN rates increased with exposure to any platinum-based agent (IRR, 3.8 [95% CI, 1.1 to 12.7]), alkylator (IRR, 4.8 [95% CI, 1.6 to 14.4]), or procarbazine (IRR, 16.9 [95% CI, 5.9 to 48.8]). Colorectal SMN rates increased linearly with procarbazine dose (ERR per 1,000 mg/m 2 = 73.0 [95% CI, 26.4% to 119.6%]) and MCD (ERR per 1 Gy = 20.8 [95% CI, 9.0% to 32.5%]). Quadratic ERR models did not improve data fit compared with linear ERR models. CONCLUSION: These RT and chemotherapy dose-response relationships can better inform contemporary RT planning for pediatric patients and surveillance guidelines for high-risk survivors.
- Open Access
- 29 May 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (7) , e70113
Developing reference plans for evaluating global clinical trials credentialing and PSQA systems
Purpose: To develop a practical framework for creating a diverse set of validated reference plans (varying in complexity) and implement a workflow to introduce beam modeling, calibration, and delivery errors into the reference cohort to test and compare various dosimetry audit methodologies. Methods: Sixteen IMRT and VMAT reference plans were created, using RayStation software, for four phantom geometries based on established credentialing cases from participating Global Harmonization Group (GHG) members. These reference plans were first validated in a multi‐ion‐chamber phantom. Nine dosimetric errors (perturbations) were introduced into the plans by modifying beam model and/or delivery parameters (MLC‐offset, MLC‐transmission, leaf‐tip‐width, PDD, beam calibration, and MLC‐position) based on documented community distributions of errors; this produced 144 plans. The dose impact on the clinical target volume (CTV) and organs at risk (OARs) was determined, and a range of classifications was developed to determine if the perturbed plan should pass or should fail an audit. Results: Introducing errors into the reference plans impacted each plan differently. Dose perturbations ranged from 10% in the mean dose to the CTV and 30% in the near maximum dose to OAR (D0.03). The 144 plans included clear “acceptable” and “unacceptable” scenarios, with significant changes in dose (relative to baseline reference values), as well as near pass/fail threshold results. Plan complexity was found to have a strong impact on dose deviation, and the mean MLC Gap metric was found to best capture this relationship. Conclusion: This study presented a framework to develop a set of reference plans and perturbations that can be used to assess and compare various audit and PSQA methodologies. The GHG has developed this framework as part of our ongoing work to test the comparability of their audit systems; this framework supports our work of aligning international dosimetry audits across the globe.
- 29 May 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (7) , e70113
Open AccessDeveloping reference plans for evaluating global clinical trials credentialing and PSQA systems
Purpose: To develop a practical framework for creating a diverse set of validated reference plans (varying in complexity) and implement a workflow to introduce beam modeling, calibration, and delivery errors into the reference cohort to test and compare various dosimetry audit methodologies. Methods: Sixteen IMRT and VMAT reference plans were created, using RayStation software, for four phantom geometries based on established credentialing cases from participating Global Harmonization Group (GHG) members. These reference plans were first validated in a multi‐ion‐chamber phantom. Nine dosimetric errors (perturbations) were introduced into the plans by modifying beam model and/or delivery parameters (MLC‐offset, MLC‐transmission, leaf‐tip‐width, PDD, beam calibration, and MLC‐position) based on documented community distributions of errors; this produced 144 plans. The dose impact on the clinical target volume (CTV) and organs at risk (OARs) was determined, and a range of classifications was developed to determine if the perturbed plan should pass or should fail an audit. Results: Introducing errors into the reference plans impacted each plan differently. Dose perturbations ranged from 10% in the mean dose to the CTV and 30% in the near maximum dose to OAR (D0.03). The 144 plans included clear “acceptable” and “unacceptable” scenarios, with significant changes in dose (relative to baseline reference values), as well as near pass/fail threshold results. Plan complexity was found to have a strong impact on dose deviation, and the mean MLC Gap metric was found to best capture this relationship. Conclusion: This study presented a framework to develop a set of reference plans and perturbations that can be used to assess and compare various audit and PSQA methodologies. The GHG has developed this framework as part of our ongoing work to test the comparability of their audit systems; this framework supports our work of aligning international dosimetry audits across the globe.
- Open Access
- 18 February 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (5) , e70017
IROC phantoms accurately detect MLC delivery errors
Purpose: We evaluated the impact of random and whole‐bank multileaf collimator (MLC) delivery errors on dosimetric delivery accuracy in the Imaging and Radiation Oncology Core (IROC) phantom audits, as well as differences in delivery accuracy between the IROC phantom prescription and typical clinical fraction sizes.Methods and Materials: Plans were created for the IROC IMRT head and neck (H&N) and SBRT spine phantoms. MLC leaf errors were introduced into the plans: random shifts between −2 and 2 mm, and whole bank shifts of 0.5, 1, and 2 mm. Plans were recalculated and delivered on a Varian Truebeam, and the log files were analyzed using Mobius Fx software. A second study examined the impact of fraction size on MLC position accuracy and corresponding dose delivery accuracy. The standard IROC phantom prescriptions (∼6 Gy) were scaled to the extremes of 2 Gy for H&N and 27 Gy for spine. All plans (original and scaled) were delivered on a Varian Truebeam and 21EX machine.Results: Random MLC positioning errors produced small average dose deviations in the PTV of up to −2.8% for H&N and 0.7% for spine. Whole‐bank MLC shifts resulted in larger average PTV dose deviations up to 8% for H&N and 7.1% for spine. The Varian 21EX irradiations had greater MLC root mean square (RMS) error than Truebeam plans. Plans with smaller prescriptions (and faster leaf motion) had greater MLC RMS errors, but plan accuracy was not affected dosimetrically – all results remained within 1% regardless of fraction size.Conclusions: Both random and whole bank MLC shifts caused dose deviations in the IROC phantoms that were comparable to clinical results previously found in the literature. Deviations measured with ion chambers were well matched with delivery log file analysis. Smaller dose‐per‐fraction prescriptions caused larger MLC RMS errors that were detected with log files, but were clinically insignificant compared to the dosimetric accuracy of the plan.
- 18 February 2025
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 26 (5) , e70017
Open AccessIROC phantoms accurately detect MLC delivery errors
Purpose: We evaluated the impact of random and whole‐bank multileaf collimator (MLC) delivery errors on dosimetric delivery accuracy in the Imaging and Radiation Oncology Core (IROC) phantom audits, as well as differences in delivery accuracy between the IROC phantom prescription and typical clinical fraction sizes.Methods and Materials: Plans were created for the IROC IMRT head and neck (H&N) and SBRT spine phantoms. MLC leaf errors were introduced into the plans: random shifts between −2 and 2 mm, and whole bank shifts of 0.5, 1, and 2 mm. Plans were recalculated and delivered on a Varian Truebeam, and the log files were analyzed using Mobius Fx software. A second study examined the impact of fraction size on MLC position accuracy and corresponding dose delivery accuracy. The standard IROC phantom prescriptions (∼6 Gy) were scaled to the extremes of 2 Gy for H&N and 27 Gy for spine. All plans (original and scaled) were delivered on a Varian Truebeam and 21EX machine.Results: Random MLC positioning errors produced small average dose deviations in the PTV of up to −2.8% for H&N and 0.7% for spine. Whole‐bank MLC shifts resulted in larger average PTV dose deviations up to 8% for H&N and 7.1% for spine. The Varian 21EX irradiations had greater MLC root mean square (RMS) error than Truebeam plans. Plans with smaller prescriptions (and faster leaf motion) had greater MLC RMS errors, but plan accuracy was not affected dosimetrically – all results remained within 1% regardless of fraction size.Conclusions: Both random and whole bank MLC shifts caused dose deviations in the IROC phantoms that were comparable to clinical results previously found in the literature. Deviations measured with ion chambers were well matched with delivery log file analysis. Smaller dose‐per‐fraction prescriptions caused larger MLC RMS errors that were detected with log files, but were clinically insignificant compared to the dosimetric accuracy of the plan.
- 1 October 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (3) , 811-821
Is the Imaging Radiation Oncology Core Head and Neck Credentialing Phantom an Effective Surrogate for Different Anatomic Sites?
- 1 October 2024
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (3) , 811-821
Is the Imaging Radiation Oncology Core Head and Neck Credentialing Phantom an Effective Surrogate for Different Anatomic Sites?
- Open Access
- 1 March 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (5) , e14318
A radiotherapy community data‐driven approach to determine which complexity metrics best predict the impact of atypical TPS beam modeling on clinical dose calculation accuracy
Purpose: To quantify the impact of treatment planning system beam model parameters, based on the actual spread in radiotherapy community data, on clinical treatment plans and determine which complexity metrics best describe the impact beam modeling errors have on dose accuracy.Methods: Ten beam modeling parameters for a Varian accelerator were modified in RayStation to match radiotherapy community data at the 2.5, 25, 50, 75, and 97.5 percentile levels. These modifications were evaluated on 25 patient cases, including prostate, non‐small cell lung, H&N, brain, and mesothelioma, generating 1,000 plan perturbations. Differences in the mean planned dose to clinical target volumes (CTV) and organs at risk (OAR) were evaluated with respect to the planned dose using the reference (50th‐percentile) parameter values. Correlation between CTV dose differences, and 18 different complexity metrics were evaluated using linear regression; R‐squared values were used to determine the best metric.Results: Perturbations to MLC offset and transmission parameters demonstrated the greatest changes in dose: up to 5.7% in CTVs and 16.7% for OARs. More complex clinical plans showed greater dose perturbation with atypical beam model parameters. The mean MLC Gap and Tongue & Groove index (TGi) complexity metrics best described the impact of TPS beam modeling variations on clinical dose delivery across all anatomical sites; similar, though not identical, trends between complexity and dose perturbation were observed among all sites.Conclusion: Extreme values for MLC offset and MLC transmission beam modeling parameters were found to most substantially impact the dose distribution of clinical plans and careful attention should be given to these beam modeling parameters. The mean MLC Gap and TGi complexity metrics were best suited to identifying clinical plans most sensitive to beam modeling errors; this could help provide focus for clinical QA in identifying unacceptable plans.
- 1 March 2024
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 25 (5) , e14318
Open AccessA radiotherapy community data‐driven approach to determine which complexity metrics best predict the impact of atypical TPS beam modeling on clinical dose calculation accuracy
Purpose: To quantify the impact of treatment planning system beam model parameters, based on the actual spread in radiotherapy community data, on clinical treatment plans and determine which complexity metrics best describe the impact beam modeling errors have on dose accuracy.Methods: Ten beam modeling parameters for a Varian accelerator were modified in RayStation to match radiotherapy community data at the 2.5, 25, 50, 75, and 97.5 percentile levels. These modifications were evaluated on 25 patient cases, including prostate, non‐small cell lung, H&N, brain, and mesothelioma, generating 1,000 plan perturbations. Differences in the mean planned dose to clinical target volumes (CTV) and organs at risk (OAR) were evaluated with respect to the planned dose using the reference (50th‐percentile) parameter values. Correlation between CTV dose differences, and 18 different complexity metrics were evaluated using linear regression; R‐squared values were used to determine the best metric.Results: Perturbations to MLC offset and transmission parameters demonstrated the greatest changes in dose: up to 5.7% in CTVs and 16.7% for OARs. More complex clinical plans showed greater dose perturbation with atypical beam model parameters. The mean MLC Gap and Tongue & Groove index (TGi) complexity metrics best described the impact of TPS beam modeling variations on clinical dose delivery across all anatomical sites; similar, though not identical, trends between complexity and dose perturbation were observed among all sites.Conclusion: Extreme values for MLC offset and MLC transmission beam modeling parameters were found to most substantially impact the dose distribution of clinical plans and careful attention should be given to these beam modeling parameters. The mean MLC Gap and TGi complexity metrics were best suited to identifying clinical plans most sensitive to beam modeling errors; this could help provide focus for clinical QA in identifying unacceptable plans.